Corporate Profile

Inotiv, Inc., provides drug discovery and development services and analytical instruments that help pharmaceutical, biotechnology, leading academic institutions and government organizations in their drug development and research efforts. Our mission is to provide drug developers with superior scientific research and innovative analytical instrumentation, which saves time, saves money, and saves lives, to bring revolutionary new drugs to market quickly and safely. Our strategy is to provide services that will generate high-quality and timely data in support of new drug approval or use expansion. To learn more about our portfolio of services, click here.

  • Click here for our latest investor presentation.
  • Investor News

    • Click here for the recording of our Q3 FY 2021 Financial Results Conference Call held Wednesday, August 11, 2021, at 4:30pm ET.
    • Click here for the recording of our Q2 FY 2021 Financial Results Conference Call held on Wednesday, May 5, 2021, at 4:30pm ET.
    • Click here to listen to the audio recording of the BASi/Inotiv 2021 Annual Meeting of Shareholders held on Thursday, March 18, 2021.
    • Click here to listen to the March 9-10, 2021, webcast of BASi/Inotiv’s presentation at the H.C. Wainwright Global Life Sciences Virtual Conference. Click here to view the presentation deck.
    • Click here for the recording of our Q1 FY 2021 Financial Results Conference Call held on Tuesday, February 9, 2021, at 4:30pm ET.
    • Click here to listen to the September 16, 2020, recording of BASi/Inotiv’s presentation at the H.C. Wainwright 22nd Annual Global Investment Conference. Click here to view the presentation deck.

    SEC Filings | Section 16 Filings

    Inotiv, Inc. Releases Earnings for Third Quarter of Fiscal 2021

    August 11, 2021​

    Results

    Investor Relations
    Beth A. Taylor, Chief Financial Officer
    Inotiv, Inc.
    765.497.8381
    Email

    Kalle Ahl, CFA
    The Equity Group
    212.836.9614
    Email

    Devin Sullivan
    The Equity Group
    212.836.9608
    Email